Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial - Concepedia

Concepedia

Publication | Open Access

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

DOI Full Paper Access

116

Citations

16

References

2019

Year

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton, Inge Christoffer Olsen, Nils Bolstad, Espen A. Haavardsholm, K. E. A. Lundin, K S Tveit, M Lorentzen, Ingrid Prytz Berset,

Journal of Internal Medicine

Abstract

The NOR-SWITCH extension showed no difference in safety and efficacy between patients who maintained CT-P13 and patients who switched from originator infliximab to CT-P13, supporting that switching from originator infliximab to CT-P13 is safe and efficacious.

References

	Year	Citations

Page 1